PET/CT imaging for prostate cancer with INR101 injection
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new imaging agent called INR101 to improve PET/CT scans for prostate cancer. It is for men with intermediate-risk or higher localized prostate cancer who are planning to have their prostate removed along with nearby lymph nodes. The goal is to see how well INR101 helps doctors see cancer during imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older
- You have been diagnosed with prostate adenocarcinoma that is intermediate-risk or higher (based on PSA, Gleason score, or tumor stage)
- You plan to have surgery to remove your prostate and some lymph nodes in your pelvis
- You have not had hormone therapy or other cancer treatments (like chemo or radiation) for this prostate cancer
- Your blood counts, kidney function, liver function, and clotting are within certain limits
- You are willing to use contraception during the study and for 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
This trial tests a new investigational drug called INR102 for prostate cancer that has spread and stopped responding to standard treatments. It's given by injection, and the study will check if it's safe and if it can shrink or slow the cancer.
This trial compares a new imaging agent (61Cu-NU101) against the current standard imaging scan (Pylarify) to see which one better detects prostate cancer that has spread to a few sites in the body. Both use PET/CT scans, which are advanced imaging tools that help doctors locate cancer.
This trial studies a new imaging agent called RAX301, which may help doctors see prostate cancer more clearly during a PET/CT scan. It is being tested in two groups of men: those scheduled for prostate removal surgery and those with a rising PSA after previous treatment.
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
This trial uses a special imaging scan (SPECT/CT) with a small amount of radioactive tracer to look at prostate cancer. It aims to see how well the scan matches your prostate cancer tests and may help improve detection and assessment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.